Magenta Therapeutics (NSDQ:MGTA) shares ticked up today on fourth-quarter earnings that topped the consensus forecast. The Cambridge, Mass.-based stem cell transplantation technology developer posted losses of -$18.2 million, or -38¢ per share for the three months ended Dec. 31, 2020, marking a 21.8% bottom-line gain. Get the full story at our sister site, Drug Delivery Business […]
magentatherapeutics
Magenta raises $50m, inks partnership with Novartis for stem cell transplant drugs
Magenta Therapeutics said today that it closed a $50 million Series B round and licensed a clinical-stage program from Novartis (NYSE:NVS) to advance its stem cell transplantation platform. The company also inked a partnership deal with Be The Match BioTherapies. Google’s venture arm, GV, led the financing round and was joined by existing investors, including […]
